Laboratorios Richmond Sociedad Anónima, Comercial, Industrial y Financiera (indistinctly, the "Issuer" or the "Company"), a regional pharmaceutical company based in Argentina that develops and produces medicines with cutting edge technology, successfully completed the issuance of Notes Series IV, under its Global Note Program for the issuance of Notes for a nominal value of up to US $50,000,000. The notes were issued on December 21, 2022 for an amount of $1.005.012.000 (pesos one thousand and five million twelve thousand), are denominated and payable in pesos; with a variable rate and maturing on March 21, 2024.
The Issuer was advised by Nicholson y Cano Abogados, while Pérez Alati, Grondona, Benites & Arntsen advised Banco Santander Argentina S.A., Neix S.A. and Invertir en Bolsa S.A. as placement agents, and Allaria Ledesma & Cía. S.A. and Banco de Valores S.A. as placement and organization agents.
The Company’s activities are focused on the development and production of medicines through the
application of cutting edge technologies, acting in a responsible manner and the environment in pursuit of sustainability. Through its subsidiaries and strategic partners, the Issuer’s products reach a large number of countries.
Advisors of Laboratorios Richmond Sociedad Anónima, Comercial, Industrial y Financiera:
Nicholson y Cano Abogados: Partner Mario Kenny. Associate Juan Martín Ferreiro.
Advisors to the Organizers and Placement Agents:
Pérez Alati, Grondona, Benites & Arntsen: Partner Diego Serrano Redonnet. Associates Nicolás
Aberastury, Nahuel Pérez de Villarreal, Joaquín López Matheu and Jerónimo Juan Argonz.
